oxotremorine has been researched along with Body Weight in 11 studies
Oxotremorine: A non-hydrolyzed muscarinic agonist used as a research tool.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The results of oxotremorine treatment suggested that they undergo strong suppression of muscarinic type acetylcholine receptors (mAChRs) functions, and that the damage in the GM3-only mice is due to a mAChR receptor deficit." | 3.76 | Dysfunction of muscarinic acetylcholine receptors as a substantial basis for progressive neurological deterioration in GM3-only mice. ( Egashira, N; Fujiwara, M; Fukue, Y; Furukawa, K; Iwasaki, K; Mishima, K; Ohmi, Y; Sugiura, Y; Tajima, O, 2010) |
| " Under these conditions, body weight, blood count and chemistry, water maze acquisition task, sensitivity to the muscarinic agonist oxotremorine, peripheral benzodiazepine receptors density and brain morphology as demonstrated by routine histopathology, remained unchanged." | 3.74 | Subchronic exposure to low-doses of the nerve agent VX: physiological, behavioral, histopathological and neurochemical studies. ( Allon, N; Bloch-Shilderman, E; Egoz, I; Gilat, E; Grauer, E; Rabinovitz, I; Raveh, L; Weissman, BA, 2008) |
| " The present experiments were performed in order to obtain more information on the relationship between the OX-induced sensitization to AMPH and the OX dose and dosing regime (single or repeated), and to find out whether the environment associated with the acute effects of OX could affect the response to AMPH." | 1.32 | Alteration in behavioral sensitivity to amphetamine after treatment with oxotremorine. Effect of dose and test environment. ( Gralewicz, S; Lutz, P; Tomas, T; Wiaderna, D, 2003) |
| "Oxotremorine was injected IV for purposes of comparison." | 1.27 | Behavioral and physiological effects associated with changes in muscarinic receptors following administration of an irreversible cholinergic agonist (BM 123). ( Booth, RA; Jenden, DJ; Russell, RW; Smith, CA; Waite, JJ, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (45.45) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tajima, O | 1 |
| Egashira, N | 1 |
| Ohmi, Y | 1 |
| Fukue, Y | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Fujiwara, M | 1 |
| Sugiura, Y | 1 |
| Furukawa, K | 2 |
| Normandin, L | 1 |
| Carrier, G | 1 |
| Gardiner, PF | 1 |
| Kennedy, G | 1 |
| Hazell, AS | 1 |
| Mergler, D | 1 |
| Butterworth, RF | 1 |
| Philippe, S | 1 |
| Zayed, J | 1 |
| Gralewicz, S | 1 |
| Lutz, P | 1 |
| Wiaderna, D | 1 |
| Tomas, T | 1 |
| Bloch-Shilderman, E | 1 |
| Rabinovitz, I | 1 |
| Egoz, I | 1 |
| Raveh, L | 1 |
| Allon, N | 1 |
| Grauer, E | 1 |
| Gilat, E | 1 |
| Weissman, BA | 1 |
| Bushnell, PJ | 1 |
| Levin, ED | 1 |
| Overstreet, DH | 2 |
| Daws, LC | 1 |
| Schiller, GD | 1 |
| Orbach, J | 1 |
| Massol, J | 2 |
| Martin, P | 2 |
| Brochet, D | 2 |
| Belon, JP | 1 |
| Puech, AJ | 1 |
| Russell, RW | 2 |
| Crocker, AD | 1 |
| Booth, RA | 2 |
| Jenden, DJ | 2 |
| Smith, CA | 1 |
| Waite, JJ | 1 |
| Puech, A | 1 |
| Simon, P | 1 |
| Widman, M | 1 |
| Tucker, S | 1 |
| Brase, DA | 1 |
| Dewey, WL | 1 |
11 other studies available for oxotremorine and Body Weight
| Article | Year |
|---|---|
Dysfunction of muscarinic acetylcholine receptors as a substantial basis for progressive neurological deterioration in GM3-only mice.
Topics: Age Factors; Aging; Animals; Body Weight; Brain; Maze Learning; Mice; Mice, Knockout; Motor Skills; | 2010 |
Assessment of bioaccumulation, neuropathology, and neurobehavior following subchronic (90 days) inhalation in Sprague-Dawley rats exposed to manganese phosphate.
Topics: Animals; Behavior, Animal; Blood Chemical Analysis; Body Weight; Electromyography; Inhalation Exposu | 2002 |
Alteration in behavioral sensitivity to amphetamine after treatment with oxotremorine. Effect of dose and test environment.
Topics: Amphetamine; Analysis of Variance; Animals; Body Weight; Dopamine Agents; Dose-Response Relationship | 2003 |
Subchronic exposure to low-doses of the nerve agent VX: physiological, behavioral, histopathological and neurochemical studies.
Topics: Animals; Behavior, Animal; Blood Cell Count; Blood Chemical Analysis; Blotting, Western; Body Weight | 2008 |
Spatial working and reference memory in rats bred for autonomic sensitivity to cholinergic stimulation: acquisition, accuracy, speed, and effects of cholinergic drugs.
Topics: Animals; Arousal; Autonomic Nervous System; Body Temperature Regulation; Body Weight; Cholinergic Ag | 1995 |
Early development of muscarinic supersensitivity in a genetic animal model of depression.
Topics: Aging; Animals; Atropine Derivatives; Body Temperature; Body Weight; Brain; Depression; Disease Mode | 1991 |
Are antidepressant-like effects of triiodothyronine (T3) in rodents related to an hyperthyroid state?
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Apomorphine; Avoidance Learning; Body Temperatu | 1989 |
Behavioral and physiological effects of an aziridinium analog of oxotremorine (BM130).
Topics: Animals; Avoidance Learning; Behavior, Animal; Body Temperature; Body Weight; Conditioning, Operant; | 1986 |
Behavioral and physiological effects associated with changes in muscarinic receptors following administration of an irreversible cholinergic agonist (BM 123).
Topics: Animals; Behavior, Animal; Body Temperature; Body Weight; Conditioning, Operant; Male; Motor Activit | 1986 |
Antidepressant-like effects of triiodothyroacetic acid in mice.
Topics: Animals; Antidepressive Agents; Apomorphine; Behavior, Animal; Body Temperature; Body Weight; Drug I | 1988 |
Cholinergic agents: antinociception without morphine type dependence in rats.
Topics: Analgesics; Animals; Body Weight; Drug Interactions; Humans; Male; Morphine; Oxotremorine; Physostig | 1985 |